Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Fusion Pharmaceuticals (Nasdaq: FUSN) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:55 p.m. ET. CFO John Crowley and CTO Eric Burak will represent the company. Investors can access a live webcast on the Company’s website, with a replay available for 60 days post-event. Fusion specializes in next-generation radiopharmaceuticals targeting tumors using alpha particle emitting isotopes. Current clinical trials include FPI-1434, FPI-1966, and FPI-2059, alongside collaborations with AstraZeneca and Merck.
- None.
- None.
HAMILTON, ON and BOSTON, Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 12:55 p.m. ET. Presenting on behalf of Fusion will be Chief Financial Officer John Crowley, and Chief Technology Officer Eric Burak, Ph.D.
A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 60 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's first program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), currently in a Phase 1 study; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), which has received FDA investigational new drug (IND) clearance and will begin a Phase 1 study. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the company has signed strategic actinium supply agreements with TRIUMF and Niowave, Inc.
For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-301619120.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
When is Fusion Pharmaceuticals presenting at the Morgan Stanley Global Healthcare Conference?
Who will represent Fusion Pharmaceuticals at the Morgan Stanley Conference?
Where can I watch the Fusion Pharmaceuticals presentation?
What is the focus of Fusion Pharmaceuticals?
What clinical trials is Fusion Pharmaceuticals currently conducting?
What collaborations does Fusion Pharmaceuticals have?
